Publication:
Droplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells.

dc.contributor.authorCarreras, Pilar
dc.contributor.authorGonzalez, Iciar
dc.contributor.authorOrtiz-Ruiz, Alejandra
dc.contributor.authorGallardo, Miguel
dc.contributor.authorMartinez-Lopez, Joaquin
dc.contributor.funderUnión Europea. Comisión Europea. H2020
dc.contributor.funderMarie Curie
dc.date.accessioned2020-11-16T09:24:00Z
dc.date.available2020-11-16T09:24:00Z
dc.date.issued2020-02-29
dc.description.abstractWe previously reported a new approach for micromanipulation and encapsulation of human stem cells using a droplet-based microfluidic device We demonstrated the possibility of encapsulating and culturing difficult-to-preserve primary human hematopoietic stem cells using an engineered double layered bead composed by an inner layer of alginate and an outer layer of puramatrix constructed using a soft technology without the use of any external force. In this work, we use this micro manipulation technique to build a 3D scaffold as a biomimetic model to recapitulate the niche of patient-derived multiple myeloma cells (MM cell) using a multilayered 3D tissue scaffold constructed in a microfluidic device and cultured in 10% FBS culture medium. In the current study, we included the use of this biomimetic model comprising supporting human Mesenchymal stem cells to show the mid-term survival of MM cells in the proposed structures. We found that the generated microniches were suitable for the maintenance of MM cells with and without supporting cells. Additionally, cultured MM cells in droplets were exposed to both Bortezomib and Lenalidomide to test their toxicity in the cultured patient derived cells. Results indicate that the maintained MM cells were consistently responding to the applied medication, opening a wide field of possibilities to use the presented micro device as an ex vivo platform for drug screening.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis research was funded by European Commission H2020 Marie Curie Research Grants Scheme MSCA-IF-GF (705163).es_ES
dc.format.number3es_ES
dc.format.volume11es_ES
dc.identifier.citationMicromachines (Basel). 2020 ;11(3):261.es_ES
dc.identifier.doi10.3390/mi11030261es_ES
dc.identifier.journalMicromachineses_ES
dc.identifier.pubmedID32121351es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11346
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.projectIDinfo:eu_repo/grantAgreement/H2020/705163es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/10.3390/mi11030261es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIOes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectDIFFERENTIATIONes_ES
dc.subjectCULTUREes_ES
dc.subjectMODELes_ES
dc.subjectINTERLEUKIN-6es_ES
dc.subjectHYDROGELSes_ES
dc.titleDroplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication9b25aa8e-597b-43e0-90d0-6d3846974c12
relation.isAuthorOfPublication.latestForDiscovery9b25aa8e-597b-43e0-90d0-6d3846974c12
relation.isFunderOfPublicationa418cf3b-f427-4376-a75f-01dba9bb944f
relation.isFunderOfPublication73586a46-a526-46a7-92a9-a1e04c95faa0
relation.isFunderOfPublication.latestForDiscoverya418cf3b-f427-4376-a75f-01dba9bb944f
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
DropletMicrofluidicsfortheexVivo_2020.pdf
Size:
2.78 MB
Format:
Adobe Portable Document Format
Description:
Artículo principal